Getinge (OTCMKTS:GNGBY) Stock Rating Upgraded by Zacks Research

Getinge (OTCMKTS:GNGBY) was upgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports.

Getinge Stock Performance

GNGBY opened at $23.96 on Tuesday. The company has a market cap of $6.53 billion, a PE ratio of 22.82 and a beta of 0.96. The stock has a 50-day moving average of $20.86 and a 200-day moving average of $21.33. Getinge has a 52-week low of $18.99 and a 52-week high of $24.67. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.86 and a current ratio of 1.32.

Getinge (OTCMKTS:GNGBY) last issued its quarterly earnings data on Friday, July 17th. The company reported $0.38 EPS for the quarter. Getinge had a return on equity of 11.67% and a net margin of 7.81%.The business had revenue of $894.87 million for the quarter. As a group, equities research analysts forecast that Getinge will post 1.38 earnings per share for the current fiscal year.

Getinge Company Profile

Getinge AB is a global medical technology company that develops, manufactures and markets products and systems for hospitals and life sciences institutions. The company’s offerings focus on critical care, surgical workflows and infection control, aiming to improve clinical outcomes and operational efficiency. Getinge’s solutions support a range of applications from intensive care and cardiovascular treatments to sterile reprocessing of surgical instruments.

The company’s product portfolio includes sterilization and disinfection equipment, surgical tables and lights, ventilation systems, heart-lung machines and extracorporeal membrane oxygenation (ECMO) devices.